Already Closing In On Imbruvica With Brukinsa, BeiGene Sets Its Sights On Another Hematology Blockbuster
Executive Summary
BeiGene is seeing rapid growth thanks to Brukinsa’s head-to-head superiority in CLL to the leading BTK inhibitor, Imbruvica, and now the company aims to repeat that feat by taking on another blood cancer big-hitter, Venclexta.